

June 15, 2020

Riken Genesis Co., Ltd.

RIKEN GENESIS and Adaptive Biotechnologies concluded distribution agreement for MRD analysis

Riken Genesis Co., Ltd. (Head Office: Shinagawa-ku, Tokyo; President & CEO: Naoto Kondo; hereinafter referred to as "RG") and Adaptive Biotechnologies Corporation (Head Office: Seattle, Washington, USA; CEO: Chad Robins; hereinafter referred to as "Adaptive") have entered into a distribution agreement for the analysis of minimal residual disease (MRD) in clinical studies in Japan.

Under the Agreement, RG will perform the clonoSEQ[®] Assay, developed by Adaptive for MRD detection and monitoring of B-cell malignancies, (e.g. acute lymphoblastic leukemia, multiple myeloma, B-cell lymphoma) using Next Generation Sequencing (NGS) to be used by clinical researchers throughout Japan.

Examination of cancer cells that remain in a patient's body during and after the treatment of lymphoid malignancies, called minimal residual disease, is considered important as an indicator of treatment response and recurrence. Previously, cytomorphologic methods were used to evaluate residual cancer cells. However, due to recent therapeutic advances, highly sensitive methods that enables reproducible detection of residual cancer cells that cannot be detected by hematologic tests are required and an important part of designing clinical trials for new therapies. clonoSEQ[®] has been successfully used in more than 200 clinical trials to date.

Our philosophy is to contribute to improving the quality of life of the people by promoting the realization of precision medicine through the cutting gene analysis technologies including NGS. So far, we have provided useful information for cancer diagnosis, treatment, and drug selection through cancer genome profiling targeting solid tumors. Through Adaptive's MRD assay, we will support the development of medical and pharmaceutical products related to lymphoid malignancies in Japan.

※clonoSEQ[®] service is available for research use only in Japan. Not approved for use in diagnostic procedures.

About Riken Genesis Co., Ltd.

Riken Genesis, established in October 2007, provides products for genetic testing based on cutting-edge genetic analysis technology and laboratory assay services with the mission of realizing precision medicine based on genome science and molecular diagnostics technology. We offer reliable trials

based on international quality standards in laboratories that have obtained CAP accreditation/ CLIA certification and ISO 15189 certification, and we have a track record in clinical sequences, support for drug discovery research, and support for clinical research. Please refer to the Riken Genesis website (URL: <https://www.riken genesis.jp/>) for more information.

About Adaptive Biotechnologies



Adaptive Biotechnologies is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature's most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed to develop products in life sciences research, clinical diagnostics, and drug discovery. We have two commercial products, and a robust clinical pipeline to diagnose, monitor and enable the treatment of diseases such as cancer, autoimmune conditions and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient. For more information, please visit adaptivebiotech.com

[Contact information]

Riken Genesis Co., Ltd. Marketing Department

Tel 03-5759-6042

Art Village Osaki Central Tower 8F, 1-2-2 Osaki, Shinagawa-ku, Tokyo 141-0032 Japan